Endotype Characterization Reveals Mechanistic Differences Across Brain Regions in Sporadic Alzheimer's Disease
- PMID: 37849634
- PMCID: PMC10578327
- DOI: 10.3233/ADR-220098
Endotype Characterization Reveals Mechanistic Differences Across Brain Regions in Sporadic Alzheimer's Disease
Abstract
Background: While Alzheimer's disease (AD) pathology is associated with altered brain structure, it is not clear whether gene expression changes mirror the onset and evolution of pathology in distinct brain regions. Deciphering the mechanisms which cause the differential manifestation of the disease across different regions has the potential to help early diagnosis.
Objective: We aimed to identify common and unique endotypes and their regulation in tangle-free neurons in sporadic AD (SAD) across six brain regions: entorhinal cortex (EC), hippocampus (HC), medial temporal gyrus (MTG), posterior cingulate (PC), superior frontal gyrus (SFG), and visual cortex (VCX).
Methods: To decipher the states of tangle-free neurons across different brain regions in human subjects afflicted with AD, we performed analysis of the neural transcriptome. We explored changes in differential gene expression, functional and transcription factor target enrichment, and co-expression gene module detection analysis to discern disease-state transcriptomic variances and characterize endotypes. Additionally, we compared our results to tangled AD neuron microarray-based study and the Allen Brain Atlas.
Results: We identified impaired neuron function in EC, MTG, PC, and VCX resulting from REST activation and reversal of mature neurons to a precursor-like state in EC, MTG, and SFG linked to SOX2 activation. Additionally, decreased neuron function and increased dedifferentiation were linked to the activation of SUZ12. Energetic deficit connected to NRF1 inactivation was found in HC, PC, and VCX.
Conclusions: Our findings suggest that SAD manifestation varies in scale and severity in different brain regions. We identify endotypes, such as energetic shortfalls, impaired neuronal function, and dedifferentiation.
Keywords: Alzheimer’s disease; NRF1; REST; SOX2; SUZ12; dedifferentiation; endotype; energetics; sporadic Alzheimer’s disease; transcriptome.
© 2023 – The authors. Published by IOS Press.
Conflict of interest statement
The authors have no conflict of interest to report.
Figures





Similar articles
-
Identification of Differentially Expressed Genes through Integrated Study of Alzheimer's Disease Affected Brain Regions.PLoS One. 2016 Apr 6;11(4):e0152342. doi: 10.1371/journal.pone.0152342. eCollection 2016. PLoS One. 2016. PMID: 27050411 Free PMC article.
-
Co-expression Network Analysis Revealing the Potential Regulatory Roles of lncRNAs in Alzheimer's Disease.Interdiscip Sci. 2019 Dec;11(4):645-654. doi: 10.1007/s12539-019-00319-w. Epub 2019 Feb 4. Interdiscip Sci. 2019. PMID: 30715720
-
A comprehensive analysis on preservation patterns of gene co-expression networks during Alzheimer's disease progression.BMC Bioinformatics. 2017 Dec 20;18(1):579. doi: 10.1186/s12859-017-1946-8. BMC Bioinformatics. 2017. PMID: 29262769 Free PMC article.
-
Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.Cochrane Database Syst Rev. 2020 Mar 2;3(3):CD009628. doi: 10.1002/14651858.CD009628.pub2. Cochrane Database Syst Rev. 2020. PMID: 32119112 Free PMC article.
-
Neural Networks in Autosomal Dominant Alzheimer's Disease: Insights From Functional Magnetic Resonance Imaging Studies.Front Aging Neurosci. 2022 Jul 19;14:903269. doi: 10.3389/fnagi.2022.903269. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35928996 Free PMC article. Review.
Cited by
-
Dual Inhibitors of Acetylcholinesterase and Monoamine Oxidase-B for the Treatment of Alzheimer's Disease.Molecules. 2025 Jul 15;30(14):2975. doi: 10.3390/molecules30142975. Molecules. 2025. PMID: 40733241 Free PMC article. Review.
-
Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer's disease.Alzheimers Res Ther. 2025 Jan 4;17(1):5. doi: 10.1186/s13195-024-01659-6. Alzheimers Res Ther. 2025. PMID: 39754192 Free PMC article.
-
Lower expression of BIN1's neuronal isoform in vulnerable excitatory neurons increases risk in Alzheimer's disease.J Alzheimers Dis Rep. 2025 Jan 13;9:25424823241296018. doi: 10.1177/25424823241296018. eCollection 2025 Jan-Dec. J Alzheimers Dis Rep. 2025. PMID: 40034505 Free PMC article.
References
-
- Hendrie HC (1998) Epidemiology of dementia and Alzheimer’s disease. Am J Geriatr Psychiatry 6, S3–18. - PubMed
-
- Tang M, Ryman DC, McDade E, Jasielec MS, Buckles VD, Cairns NJ, Fagan AM, Goate A, Marcus DS, Xiong C, Allegri RF, Chhatwal JP, Danek A, Farlow MR, Fox NC, Ghetti B, Graff-Radford NR, Laske C, Martins RN, Masters CL, Mayeux RP, Ringman JM, Rossor MN, Salloway SP, Schofield PR, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network (DIAN) (2016) Neurological manifestations of autosomal dominant familial Alzheimer’s disease: A comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol 15, 1317–1325. Erratum in: Lancet Neurol. 2017 Jan;16(1):24. - PMC - PubMed
-
- Shepherd C, McCann H, Halliday GM (2009) Variations in the neuropathology of familial Alzheimer’s disease. Acta Neuropathol (Berl) 118, 37–52. - PubMed
-
- Roher AE, Maarouf CL, Kokjohn TA (2016) Familial presenilin mutations and sporadic Alzheimer’s disease pathology: Is the assumption of biochemical equivalence justified? J Alzheimers Dis 50, 645–658. - PubMed